Chondroitin Sulfate for Crohn's Disease

Summary

Pilot trial of open-label chondroitin sulfate 400 mg TID for adult patients with mild to moderate Crohn's disease. Primary endpoint with be evidence of bilogic effect assessed through serum and tissue cytokine analysis. Secondary endpoints are evidence of clinical effect, endoscopic healing, and histologic improvment. Trial duration is 8 weeks.

Timeline

Start

2011-01

Primary completion

2012-03

Completion

2012-05

Drugs

Indications